Nivolumab (Opdivo?) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor and selectively blocks interaction with its programmed death ligands PD-L1 and PD-L2. Upregulation of PD-1 ligands occurs in some tumors and signalling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumour tissue. The inhibitory effect of PD-1 and its ligands occurs through the promotion of apoptosis in antigen specific T cells while simultaneously blocking apoptosis in suppressor T cells. Blocking PD-1 activity has been shown to lead to decreased tumour growth in mouse tumour models. BioSim? Nivolumab ELISA kit has been developed for specific quantification of Nivolumab concentration in human serum or plasma with high sensitivity and reproducibility.
產品特點
? Easy, convenient, sensitive and time-saving method to measure the level of Nivolumab in human serum and plasma.
? Detection Range: 30 - 3000 ng/ml
? Sensitivity: 10 ng/ml
? Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
? Recovery rate: 85 – 115% with normal human serum samples with known concentrations
? Cross Reactivity: Except for Nivolumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins
